Semaglutide-based medications, known as GLP-1 agonists, mimic a hormone that enhances insulin production and suppresses appetite, aiding in weight loss and blood sugar control.

“The results from this landmark study across 37 countries provide strong evidence that semaglutide can help patients with MASH by not only improving liver health, but also addressing the ...

The researchers found that based on 551 cases, there were an estimated 24,499 emergency department visits attributed to semaglutide adverse events in 2022 through 2023 (mean patient age, 50.9 ...